Candel Therapeutics CEO to Present at TD Cowen Health Care Conference
Event summary
- Candel Therapeutics CEO Paul Peter Tak to present at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026.
- Presentation scheduled for 11:50 AM - 12:20 PM ET.
- Webcast available via Candel’s Investors section, replay archived for 90 days.
- Candel’s lead product candidate, aglatimagene besadenovec, completed phase 2a trials in NSCLC and PDAC, and phase 3 trial in prostate cancer.
- Linoserpaturev in phase 1b trial for recurrent high-grade glioma, with initial results published in Nature and Science Translational Medicine.
The big picture
Candel Therapeutics is positioning itself as a key player in the oncology immunotherapy sector, with a focus on off-the-shelf multimodal biological immunotherapies. The company’s strategic emphasis on regulatory designations and clinical trial advancements underscores its push to bring innovative cancer treatments to market. The upcoming presentation at TD Cowen’s conference provides a platform to showcase these developments to investors and industry stakeholders.
What we're watching
- Regulatory Progress
- Whether Candel can leverage FDA designations to accelerate approval timelines for aglatimagene besadenovec.
- Clinical Trial Outcomes
- The pace at which phase 1b trial results for linoserpaturev will influence further development and investment.
- Market Positioning
- How Candel’s multimodal immunotherapy approach differentiates it in the competitive oncology space.
Related topics